NOVO — Oktober 2025
-
Michael Novod, Nordea, går til Novo jf. Børsen.
-
Novo bliver udstillet, godt og grundigt, i udviklingen på C25 idag. En trøst er, at der er uanede muligheder for forbedring.....
-
Novo Nordisks kursmål skæres af Jyske Bank: Ny indsnævring af forventningerne en mulighed https://proinvestor.com/investornyt/1373952/novo-nordisks-kursmal-skaeres-af-jyske-bank-ny-indsnaevring-af-forventningerne-en-mulighed
-
Ugens største nyhed var uden tvivl, at Novo Nordisk bestyrelse går af, og Lars Rebien bliver formand. Det kigger Helge Larsen nærmere på og giver også en status på situationen med Bavarian Nordic og Anavex, og slutteligt omtaler han et flot kvartalsregnskab fra Embla. Kort video: https://proinvestor.com/boards/129106
-
-
Meget informativt: Hvor ER den mand dygtig til at få sagt de ting, der skal siges, på den mest tiltalende - og samtidig meget glatte - måde, der kan tænkes! En mester i smooth communication: - En sand amerikaner... Indhold: Ikke noget udover at NOVO er i dialog med FDA - og ingen ting tyder på en udsættelse af Wpillen.
-
CEO of Novo Nordisk Mike Doustdar wrote the following on LinkedIn: "This is remarkable: new research published in Lancet Group analysed Novo Nordisk product data and found cardiovascular benefits that seem to operate independently of weight reduction. This is the type of headline I had to pause and read twice. The study results suggest that cardiovascular benefits may extend beyond traditional weight loss outcomes, pointing to broader health impacts....
-
This is exactly why Novo Nordisk is focused on bringing innovation to more people - to help treat the multiple chronic diseases that often go hand in hand. We're not just addressing one condition in isolation, but the interconnected web of health challenges people face.
-
These breakthrough medicines are making headlines, but have you wondered about how they actually work in the body? And what makes them different from traditional treatments? Check out this explainer to learn more. The science behind these medicines tells a story about treating the whole person, not just individual symptoms. That's the future of healthcare".
-
-
Dermatologic and Metabolic Benefits of Semaglutide in Psoriasis with Obesity: A Six-Month Prospective Cohort Study : https://academic.oup.com/ced/advance-article-abstract/doi/10.1093/ced/llaf473/8301164?login=false
-
Conclussion: In patients with psoriasis and obesity, semaglutide improves both skin disease and systemic health. The clinical benefit appears associated with specific fat loss and psychosocial improvement, beyond overall weight reduction.
-
UK seizes record haul of illegal weight-loss drugs in factory raid
By Sam Tabahriti
October 25, 20251:20 AM GMT+2Updated October 25, 2025 https://www.reuters.com/sustainability/boards-policy-regulation/uk-seizes-record-haul-illegal-weight-loss-drugs-factory-raid-2025-10-24/ -
Novo får rundbarberet kursmålet hos Jefferies: Patentudløb giver udfordringer https://proinvestor.com/investornyt/1375051/novo-far-rundbarberet-kursmalet-hos-jefferies-patentudlob-giver-udfordringer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind